Can-Fite Biopharma Ltd ADR(CANF) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 30 at 4:51 PM ET (Korea 10/1 05:51)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -6.3 | Insider Own | - | Shs Outstand | 0.2M | Perf Week | 1.85% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 55.39% | Insider Trans | - | Shs Float | - | Perf Month | -30.82% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | -0.8 | Inst Own | 1.66% | Short Float | - | Perf Quarter | -52.48% |
| Income | -0.01B | P/S | 16.26 | EPS this Y | 65.83% | Inst Trans | -5.22% | Short Ratio | 0.04 | Perf Half Y | -29.03% |
| Sales | 0.00B | P/B | 0.97 | EPS next 5Y | 52.5% | ROA | -121.89% | Short Interest | 0.06M | Perf YTD | -45% |
| Book/sh | 2.27 | P/C | 0.95 | EPS past 3/5Y | 45.54% 45.72% | ROE | -212.72% | 52W High | -82.81% ($12.80) | Perf Year | -82.24% |
| Cash/sh | 2.32 | P/FCF | - | Sales past 3/5Y | -20.32% -11.88% | ROIC | -197.98% | 52W Low | 2.8% ($2.14) | Perf 3Y | -95.85% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 82.96% | Gross Margin | 99.51% | Volatility(W/M) | 3.64% 4.99% | Perf 5Y | -99.34% |
| Dividend TTM | - | EV/Sales | -0.79 | Sales Y/Y TTM | - | Oper. Margin | -2402.92% | ATR (14) | 0.12 | Perf 10Y | -99.97% |
| Dividend Ex-Date | - | Quick Ratio | 3.6 | EPS Q/Q | 66.85% | Profit Margin | -2358.72% | RSI (14) | 34.04 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.6 | Sales Q/Q | -20.25% | SMA20 | -1.61% ($2.24) | Beta | 1.15 | Target Price | $8 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/9/8 | SMA50 | -23.68% ($2.88) | Rel Volume | 0.05 | Prev Close | $2.18 |
| Employees | 5 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -37.12% ($3.5) | Avg Volume(3M) | 1.32M | Price | $2.2 |
| IPO | 2012/11/1 | Option/Short | No/Yes | Trades | 312 | Volume | 61,110 | Change | 0.92% |
🧪 This Israel-based clinical-stage biotech holds two small-molecule drug candidates targeting the A3 adenosine receptor (A3AR)—piclidenoson and namodenoson—as its core assets. It is a micro-cap ADR running late-stage clinical trials across a broad range of indications, including liver cancer, psoriasis, pancreatic cancer, and MASH.
Over the past 1 year, on the lower side
83% below its 1-year high.
Traded less than usual That is 5% of its average volume.
CANF has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +65.8% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,626. Peers typically go for $1,243.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.3%. The S&P 500 did +78% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 1.7%.
Tap to view numbers
It ranks #537 of 592 in the industry
Based on market cap of $7M.
AIM#536 AIM ImmunoTech Inc $7M PER - CANF#537 Can-Fite Biopharma Ltd ADR $7M PER - 
ENVB#537 Enveric Biosciences Inc $7M PER - 
LNAI#539 Lunai Bioworks Inc $7M PER - 
LEXX#540 Lexaria Bioscience Corp $7M PER - 
FAQ
What kind of company is CANF?
CANF belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CANF?
The market cap of CANF is approximately $7M, ranking 5,614 within its sector.
What is the 52-week high and low for CANF?
CANF has recorded a 52-week high of $12.80 and a low of $2.14.
